Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/104263
Title: CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
Author: Montraveta, Arnau
Lee-Vergés, Eriong
Roldán, Jocabed
Jiménez, Laura
Cabezas, Sandra
Clot, Guillem
Pinyol, Magda
Xargay i Torrent, Sílvia
Rosich, Laia
Arimany-Nardí, Cristina
Aymerich Gregorio, Marta
Villamor i Casas, Neus
López Guillermo, Armando
Pérez-Galán, Patricia
Roué, Gaël
Pastor Anglada, Marçal
Campo Güerri, Elias
López Guerra, Mónica
Colomer Pujol, Dolors
Keywords: Leucèmia limfocítica crònica
Limfomes
Quimioteràpia
Marcadors bioquímics
Medicaments
Chronic lymphocytic leukemia
Lymphomas
Chemotherapy
Biochemical markers
Drugs
Issue Date: 19-Dec-2015
Publisher: Impact Journals
Abstract: Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly heterogeneous and no specific markers to predict sensitivity to this drug have been reported. In order to identify biomarkers of response, we analyzed the in vitro activity of bendamustine and the gene expression profile in primary CLL cells. We observed that mRNA expression of CD69 (CD69) and ITGAM (CD11b) constitute the most powerful predictor of response to bendamustine. When we interrogated the predictive value of the corresponding cell surface proteins, the expression of the activation marker CD69 was the most reliable predictor of sensitivity to bendamustine. Importantly, a multivariate analysis revealed that the predictive value of CD69 expression was independent from other clinico-biological CLL features. We also showed that when CLL cells were co-cultured with distinct subtypes of stromal cells, an upregulation of CD69 was accompanied by a reduced sensitivity to bendamustine. In agreement with this, tumor cells derived from lymphoid tumor niches harbored higher CD69 expression and were less sensitive to bendamustine than their peripheral blood counterparts. Furthermore, pretreatment of CD69 high CLL cases with the B-cell receptor (BCR) pathway inhibitors ibrutinib and idelalisib decreased CD69 levels and enhanced bendamustine cytotoxic effect. Collectively, our findings indicate that CD69 could be a predictor of bendamustine response in CLL patients and the combination of clinically-tested BCR signaling inhibitors with bendamustine may represent a promising strategy for bendamustine low responsive CLL cases.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.6685
It is part of: Oncotarget, 2015, vol. 7, num. 5, p. 5507-5520
Related resource: https://doi.org/10.18632/oncotarget.6685
URI: http://hdl.handle.net/2445/104263
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
656888.pdf1.44 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons